KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Research & Development (2016 - 2026)

Eli Lilly filings provide 18 years of Research & Development readings, the most recent being $3.5 billion for Q1 2026.

  • On a quarterly basis, Research & Development rose 28.38% to $3.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $14.1 billion, a 25.99% increase, with the full-year FY2025 number at $13.3 billion, up 21.34% from a year prior.
  • Research & Development hit $3.5 billion in Q1 2026 for Eli Lilly, down from $3.8 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.8 billion in Q4 2025 to a low of $1.6 billion in Q1 2022.
  • Median Research & Development over the past 5 years was $2.6 billion (2023), compared with a mean of $2.6 billion.
  • Biggest five-year swings in Research & Development: fell 3.71% in 2022 and later soared 33.62% in 2023.
  • Eli Lilly's Research & Development stood at $2.0 billion in 2022, then increased by 28.38% to $2.6 billion in 2023, then rose by 17.98% to $3.0 billion in 2024, then grew by 25.76% to $3.8 billion in 2025, then decreased by 7.67% to $3.5 billion in 2026.
  • The last three reported values for Research & Development were $3.5 billion (Q1 2026), $3.8 billion (Q4 2025), and $3.5 billion (Q3 2025) per Business Quant data.